Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High Following Analyst Upgrade
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) shares reached a new 52-week high on Monday after HC Wainwright raised their price target on the stock from $7.50 to $12.50. HC Wainwright currently has a buy rating on the stock. Trevi Therapeutics traded as high as $7.39 and last traded at $6.49, with a volume […]
